High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction : Results of a phase II study of the Eastern Cooperative Oncology Group

• Published in: Cancer Vol. 83; no. 9; pp. 1908 - 1916
• Main Authors: KELLER, S. M, RYAN, L. M, COIA, L. R, PHUONG DANG, VAUGHT, D. J, DIGGS, C, WEINER, L. M, BENSON, A. B
• Format: Conference Proceeding Journal Article
• Language: English
• Published: New York, NY Wiley-Liss 01.11.1998
• Subjects: Adenocarcinoma - therapy; Adult; Aged; Antineoplastic agents; Biological and medical sciences; Chemotherapy, Adjuvant; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Dose-Response Relationship, Drug; Esophageal Neoplasms - therapy; Esophagectomy; Female; Humans; Male; Medical sciences; Middle Aged; Neoadjuvant Therapy; Pharmacology. Drug treatments; Radiotherapy, Adjuvant; Stomach Neoplasms - therapy; Treatment Outcome; Adenocarcinoma; Antineoplastic agent; Human; Mitomycin; Prognosis; Fluoropyrimidine derivatives; Esophageal disease; Esophagectomy; Malignant tumor; Radiotherapy; Esophagus; Antibiotic; Chemotherapy; Treatment; Gastroesophageal junction; Surgery; Phase II trial; Digestive diseases; Combined treatment; Fluorine Organic compounds; Preoperative; Gastric disease; Fluorouracil
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/(SICI)1097-0142(19981101)83:9<1908::AID-CNCR5>3.0.CO;2-6

To assess the toxicity, local response, and survival associated with multimodality therapy in a cooperative group setting, patients with biopsy-proven clinical Stage I or II adenocarcinoma of the esophagus (staged according to 1983 American Joint Committee on Cancer criteria) or gastroesophageal junction were treated with concomitant radiation and chemotherapy followed by esophagectomy. Radiotherapy was administered in daily 2-gray (Gy) fractions 5 days a week until a total of 60 Gy was reached. 5-fluorouracil (5-FU) was infused continuously at a dose of 1000 mg/m2/day for 96 hours on Days 2-5 and 28-31. On Day 2, a 10 mg/m2 bolus of mitomycin was injected intravenously. Esophagectomy was performed 4-8 weeks following completion of the radiotherapy. During the 18-month study period (August 1991 through January 1993), 46 eligible patients were accrued from 21 institutions. Eight patients were Stage I and 38 Stage II. Eighty-seven percent of patients (40 of 46) received 6000 centigray (cGy), and all received >5000 cGy. Seventy-eight percent of patients (36 of 46) received >90% of the planned 5-FU dose. Follow-up ranged from 11 to 36 months (median, 22 months). There were eight treatment-related deaths; two were preoperative (from adult respiratory distress syndrome) and six were postoperative. Complete or partial response prior to esophagectomy was observed in 63% of cases, stable disease in 15%, and progression in 20%. Thirty-three patients underwent esophagectomy (transhiatal, n=14; Ivor Lewis, n=16; other, n=3). No tumor was found in the specimens resected from 8 of these 33 patients; this represented a pathologic complete response rate of 17% overall and 24% for those who underwent esophagectomy. Overall median survival was 16.6 months, 1-year survival 57%, and 2-year survival 27%. Survival was significantly worse for patients with circumferential cancers (median, 18.1 months vs. 8.3 months; P <0.05). High dose radiation therapy with concurrent 5-FU and mitomycin may be administered to patients with esophageal adenocarcinoma with acceptable morbidity. However, in a cooperative group setting, esophagogastrectomy following intensive chemoradiotherapy is associated with excessive morbidity and mortality. Circumferential tumor growth is a significant adverse prognostic factor.